This research delved into the development of novel potential cancer drugs targeting class 1 histone deacetylases (HDACs) and highlights the promise of two specific ligands, LIG1 and LIG2, as potent HDAC inhibitors with potential applications in cervical cancer treatment. The gene discussed is HDAC9; the disease is cervical carcinoma.